|
2021
|
Invention
|
Topical use of levofloxacin for reducing lung inflammation.
The present invention relates to met... |
|
|
Invention
|
Aerosolized fluoroquinolones and uses thereof.
Disclosed herein are formulations of fluoroquinol... |
|
|
Invention
|
Ado-resistant cysteamine analogs and uses thereof. The present disclosure is directed to methods ... |
|
2020
|
Invention
|
Use of aerosolized levofloxacin for treating cystic fibrosis.
Methods for treating cystic fibros... |
|
|
Invention
|
Aerosol fluoroquinolone formulations for improved pharmacokinetics.
The present invention relate... |
|
|
Invention
|
Methods of treating a pulmonary bacterial infection using fluoroquinolones.
Disclosed herein are... |
|
2019
|
Invention
|
Methods for storing cysteamine formulations and related methods of treatment. Methods of storing ... |
|
|
Invention
|
Methods of treating excitotoxicity disorders.
The present disclosure relates in general to metho... |
|
|
Invention
|
Methods of treating excitotoxicity disorders. The present disclosure relates in general to method... |
|
|
Invention
|
Use of aerosolized levofloxacin for treating cystic fibrosis. P. aeruginosa. |
|
|
Invention
|
Aerosolized fluoroquinolones and uses thereof. Disclosed herein are formulations of fluoroquinolo... |
|
2018
|
Invention
|
Delayed release cysteamine bead formulation, and methods of making and using same. An enteric-coa... |
|
|
Invention
|
Aerosol fluoroquinolone formulations for improved pharmacokinetics. The present invention relates... |
|
|
G/S
|
Pharmaceutical preparations for treating cystinosis and nephropathic cystinosis; pharmaceutical p... |
|
|
Invention
|
Fucosidase inhibitors. The present disclosure relates, in general, to compounds useful as inhibit... |
|
|
Invention
|
Methods for analyzing cysteamine compositions.
Methods of analyzing purity of compositions compr... |
|
2017
|
Invention
|
Compositions comprising receptor-associated protein (rap) variants specific for cr-containing pro... |
|
|
Invention
|
Genotype specific methods for treating human subjects using 4-methylpyrazole.
Provided herein ar... |
|
|
Invention
|
Topical use of levofloxacin for reducing lung inflammation. The present invention relates to meth... |
|
|
Invention
|
Delayed release cysteamine bead formulation, and methods of making and using same.
An enteric-co... |
|
|
Invention
|
Fluoroquinolone formulations for cystic fibrosis.
The disclosure provides methods for treating c... |
|
|
Invention
|
Fluoroquinolone formulations for cystic fibrosis. The disclosure provides methods for treating cy... |
|
2016
|
Invention
|
Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine compounds. The disclosu... |
|
|
Invention
|
Ado-resistant cysteamine analogs and uses thereof. The present invention is directed to ADO-resis... |
|
|
Invention
|
4-methylpyrazole formulations for inhibiting ethanol intolerance.
Provided herein are methods, c... |
|
2015
|
Invention
|
Methods of treating huntington's disease using cysteamine compositions. The present disclosure re... |
|
|
Invention
|
Methods of treating huntington's disease using cysteamine compositions.
The present disclosure r... |
|
|
Invention
|
4-methylpyrazole formulations.
Provided herein are 4-methylpyrazole (4-MP) formulations, stable ... |
|
|
G/S
|
Providing medical information in the field of cystinosis; providing medical information in the fi... |
|
2014
|
Invention
|
Use of cysteamine and derivatives thereof to treat mitochondrial diseases.
The present disclosur... |
